8-K: Alto Neuroscience Acquires Novel Dopamine Agonist Portfolio, Bolstering Late-Stage Pipeline in Treatment-Resistant Depression

Alto Neuroscience, Inc. announced the acquisition of a portfolio of dopamine agonist drug combinations from Chase Therapeutics Corporation, including ALTO-207 for treatment-resistant depression, extending its cash runway into 2028.

Summary

• Alto Neuroscience, Inc. acquired rights, title, and interest in certain assets related to CTC-501 (now ALTO-207) and CTC-413 (now ALTO-208) from Chase Therapeutics Corporation via an Asset Purchase Agreement on May 31, 2025.
• The Company made an initial payment of $1,750,000 in cash and reimbursed the Seller $1,200,000 for certain expenses, totaling $2,950,000 upfront.
• Alto is obligated to pay the Seller up to an aggregate of $71,500,000 in Milestone Payments upon the achievement of certain clinical, regulatory, and sales milestones, with $41,000,000 tied to commercial success.
• The Seller may elect to receive Milestone Payments in cash or restricted shares of Alto's common stock, subject to a maximum issuance of 5,387,353 shares (representing 19.9% of outstanding shares as of the Closing Date).
• ALTO-207 (formerly CTC-501), a fixed-dose combination of pramipexole and ondansetron, is being developed for Treatment Resistant Depression (TRD).
• ALTO-207 met primary and secondary endpoints in a completed Phase 2a study in Major Depressive Disorder (MDD), demonstrating significantly greater improvements on MADRS (Week 8 Cohens d = 1.1, p<0.05) and CGI-S (Week 8 Cohens d=1.0, p=0.04) compared to placebo.
• ALTO-208 (formerly CTC-413), a fixed-dose combination of pramipexole and aprepitant, is being developed for Parkinson's disease, showing significantly higher tolerated doses in a Phase 2a trial (p<0.001).
• Alto expects to initiate a Phase 2b trial for ALTO-207 in TRD by mid-2026 and report topline data in 2027.
• The Company's cash guidance remains unchanged, with current cash expected to fund planned operations into 2028, covering at least five planned clinical study readouts.

Sentiment

Score: 8

Explanation: The acquisition significantly strengthens Alto's pipeline with a late-stage asset showing strong clinical data, without impacting the company's cash runway, which is extended into 2028. This indicates strong strategic execution and financial stability for a clinical-stage company, addressing a high unmet medical need.

Positives

• Acquisition of ALTO-207, a late-stage, potentially pivotal product candidate for Treatment Resistant Depression (TRD), addressing a significant unmet medical need.
• ALTO-207 demonstrated robust clinical effects in a completed Phase 2a study, with large and clinically meaningful improvements on depression symptom scales (Cohen's d of 1.1 for MADRS and 1.0 for CGI-S).
• The fixed-dose combination of ALTO-207 is designed to enable rapid titration and higher dosing of pramipexole by mitigating dose-limiting adverse events, enhancing its therapeutic potential.
• The acquisition expands Alto's pipeline without impacting its current cash runway, which is projected to extend into 2028, covering at least five clinical study readouts.
• ALTO-208, acquired for Parkinson's disease, showed improved tolerability and higher tolerated doses in its Phase 2a trial.
• The transaction leverages Alto's proprietary insights on dopamine biomarkers in depression, positioning the company to optimize the development of ALTO-207.

Negatives

• The acquisition involves significant future contingent milestone payments of up to $71,500,000, which are dependent on the successful achievement of clinical, regulatory, and commercial milestones.
• Alto is obligated to either pre-pay a portion of relevant milestone payments or transfer the related Acquired Compound back to the Seller if certain Milestone Events are not achieved by agreed dates, posing a potential financial or asset loss risk.

Risks

• Uncertainties inherent in the initiation, progress, and completion of clinical trials for ALTO-207 and ALTO-208.
• The reproducibility of positive clinical data seen in prior trials of CTC-501/ALTO-207 is not guaranteed in future studies.
• Actual results or events could differ materially from forward-looking statements due to various factors, including those detailed in Alto's SEC filings.
• Failure to achieve certain Milestone Events by agreed dates could trigger obligations to pre-pay portions of milestone payments or transfer the acquired compounds back to the Seller.
• The ultimate commercial success and regulatory approval of the acquired compounds are not guaranteed and are subject to significant market and regulatory factors.

Future Outlook

Alto Neuroscience expects to initiate a potentially pivotal Phase 2b trial for ALTO-207 in treatment-resistant depression by mid-2026, with topline data anticipated in 2027. The company's current cash balance is projected to fund planned operations into 2028, covering at least five planned clinical study readouts across its pipeline programs.

Management Comments

• "The expansion of our pipeline aligns with Altos mission to drive innovation in psychiatry through novel therapeutic solutions." Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience.
• "With proprietary insights on dopamine biomarkers in depression that enable targeted neuropsychiatric drug development, we are uniquely positioned to advance ALTO-207, a differentiated, late-stage product candidate with robust clinical effects to date, which are supported with historical pramipexole data." Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience.
• "The strategic transaction with Chase Therapeutics allows us to add a major late-stage clinical readout to our pipeline without changing our current cash runway guidance into 2028." Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience.
• "Supported by the robust clinical effects in our completed Phase 2a study, we believe CTC-501, has the potential to address the critical need for more effective, mechanistically distinct interventions for patients with TRD." Thomas Chase, M.D., President and Chief Executive Officer of Chase Therapeutics Corporation.
• "Given Altos expertise in dopamine-related products in depression, we believe they are an ideal partner to maximize the therapeutic potential of our portfolio in depression and Parkinsons disease." Thomas Chase, M.D., President and Chief Executive Officer of Chase Therapeutics Corporation.

Industry Context

The acquisition of ALTO-207 and ALTO-208 positions Alto Neuroscience to address significant unmet needs in treatment-resistant depression (TRD) and Parkinson's disease. TRD affects a substantial patient population who have failed multiple antidepressant treatments, highlighting the demand for novel, effective interventions. The focus on dopamine agonists and the use of a fixed-dose combination to mitigate side effects represents an innovative approach in neuropsychiatric drug development, potentially offering a differentiated therapeutic option compared to existing treatments. Alto's Precision Psychiatry Platform, which uses biomarkers to identify responders, aligns with the broader industry trend towards personalized medicine in psychiatry.

Comparison to Industry Standards

• The Phase 2a results for ALTO-207 (CTC-501) in MDD showed a Cohen's d of 1.1 on MADRS and 1.0 on CGI-S, which are considered large and clinically meaningful effect sizes, potentially exceeding those of some currently available TRD treatments, as suggested by Professor Michael Browning's commentary on the PAX-D study of pramipexole.
• The fixed-dose combination approach of ALTO-207 aims to improve tolerability and enable higher dosing of pramipexole, directly addressing a known limitation of pramipexole monotherapy (dose-limiting adverse events and slow titration) that has historically hindered its broader clinical utility in depression.
• The ability to extend the cash runway into 2028 while simultaneously adding a late-stage asset is a strong financial position for a clinical-stage biopharmaceutical company, allowing for multiple clinical readouts without an immediate need for additional capital, which is a favorable comparison to many peers in the sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased company value due to pipeline expansion, addition of a late-stage asset with positive clinical data, and extended cash runway. There is a potential for dilution from the issuance of up to 5,387,353 shares for milestone payments (19.9% of outstanding shares).
• Patients: Potential for new, more effective, and better-tolerated treatment options for Treatment Resistant Depression and Parkinson's disease.
• Employees: Potential for increased research and development activities, leading to growth opportunities and expanded roles within the company.
• Chase Therapeutics Corporation (Seller): Receives an upfront cash payment and is eligible for significant future milestone payments, with the option to receive payments in Alto's common stock, aligning their financial interests with Alto's success.

Next Steps

• Alto Neuroscience expects to initiate a Phase 2b trial for ALTO-207 in Treatment Resistant Depression by mid-2026.
• Topline data for the ALTO-207 Phase 2b trial is expected in 2027.
• The complete Asset Purchase Agreement will be filed with the Securities and Exchange Commission in Alto's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.
• The Company and Seller agreed to negotiate, in good faith, a customary registration rights agreement with respect to the shares of Common Stock that may be delivered to Seller.

Key Dates

Recommendation

Keywords

Alto Neuroscience, ANRO, Chase Therapeutics, ALTO-207, CTC-501, ALTO-208, CTC-413, Treatment Resistant Depression, TRD, Parkinson's Disease, Pramipexole, Ondansetron, Aprepitant, Dopamine Agonist, Neuropsychiatric Disorders, Clinical Trial, Phase 2a, Phase 2b, Asset Purchase Agreement, Biopharmaceutical, Precision Psychiatry Platform, SEC Filing, 8-K